TCI GENE Inc. (TPEX:6879)

Market Cap	940.60M -16.4%
Revenue (ttm)	251.39M -22.6%
Net Income	50.62M +41.4%
EPS	1.90 +37.6%
Shares Out	26.46M
PE Ratio	18.73
Forward PE	n/a
Dividend	2.00 (5.88%)
Ex-Dividend Date	Sep 5, 2025

Volume	20
Open	35.55
Previous Close	35.55
Day's Range	35.55 - 35.55
52-Week Range	32.35 - 46.00
Beta	0.27
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2026

About TCI GENE

TCI GENE Inc., together with its subsidiaries, provides genetic testing and assessment services in Taiwan and Mainland China. It operates through Inspection and Consumable Products segments. The company offers memory, anti-aging, health management, child growth and development, nutritional metabolism and absorption, OB weight management, and SC skin management genetic testing; gut microbiota testing; and LDT cardiovascular drug gene testing services. It also provides precision prediction and personalized health management plans; and adipose-der...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6879

Financial Performance

In 2025, TCI GENE's revenue was 273.61 million, a decrease of -21.27% compared to the previous year's 347.54 million. Earnings were 40.57 million, a decrease of -27.96%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 26, 2026

Data Sources Report a data error